93 results about "Oral hypoglycemic" patented technology

This invention relates to a series of substituted cyclohexane containing analogues which are agonists of GPR119 intended to treat metabolic diseases mediated by GPR119 including Type I & II diabetes mellitus. Diabetes mellitus is an ever-increasing threat to human health causing various complications (blindness, kidney failure, neuropathy, heart attack, stroke, etc.). Recently it was found that activation of GPR119 which is highly expressed in pancreatic beta cells causes glucose dependent insulin secretion and GLP-1 release. Many pharmaceuticals are currently developing GPR119 agonists and herein we disclose alternative GPR119 agonists. Our invention describes GPR119 agonists having structural Formula (I), pharmaceutically acceptable salt or solvate of Formula (I), isomer or prodrug of Formula (I), and combination therapy of Formula (I) with other anti-diabetic drugs like DPP-IV inhibitors and / or insulin sensitizers.

Oral hypoglycemic polypeptide is an Exendin-4 analogue and is obtained by replacing twelfth, twentieth and twenty-seventh amino acids in an amino acid sequence of the Exendin-4 with non basic amino acids. Compared with an Exendin-4 archetype, the enzymatic hydrolysis resistance of the oral hypoglycemic polypeptide is remarkably improved, and the hypoglycemic polypeptide can be orally taken and has a good application prospect in treatment of type II diabetes mellitus.

The invention relates to a health care tea capable of reducing blood sugar and a preparation method thereof and belongs to the technical field of natural plant processing. The preparation method comprises the following steps of: cleaning fresh sweet potato leaves, mulberry leaves and tea leaves, soaking with electrolysed water, removing green, and then drying; and mixing in proportion, carrying out coarse crushing, and drying, so that the health care tea capable of reducing blood sugar is prepared. Clinical verifications show that the conventional oral blood sugar reducing medicine and the health care tea capable of reducing blood sugar provided by the invention can enhance the blood sugar reducing effect of a blood sugar reducing medicine and also obviously relieve symptoms such as swirl, thirst, fatigue, soreness of waist and leg weakness, and the total effective rate is 89%. The health care tea provided by the invention is unique in taste and has good blood sugar reducing health care function.

The invention provides a compound having an alpha-glucosidase inhibitory activity in lotus leaves. Nine compounds having the alpha-glucosidase inhibitory activity are screened from the lotus leaves through magnetic bead separation and liquid chromatogram-mass spectrometry analysis, and the obtained compounds are confirmed to have the alpha-glucosidase inhibitory activity through a verification of the alpha-glucosidase inhibitory activity. Compared with tradition methods, separated compounds are not needed to prepare during a primary screening, thereby substantially improving screening efficiency and shortening screening time. Due to changing a traditional activity-screening mode which separates firstly and screens secondly to a novel activity-screening mode which screens firstly and separates secondly, blindness of preparing and separating compounds is greatly reduced. The method can be popularized and applied to quick screening of compounds having the alpha-glucosidase inhibitory activity from natural medicines or herbal mixtures. The obtained compounds can be used for preparing anti-diabetic drugs.

The present invention provides pharmaceutical compositions and methods for the treatment of diabetes mellitus using combination therapy. The compositions relate to a compound of Formula I and an antidiabetic agent such as sulfonylureas, biguanides, glitazones, α-glucosidase inhibitors, potassium channel antagonists, aldose reductase inhibitors, glucagon antagonists, activators of RXR, insulin therapy or other anti-obesity agent. The methods include the administration of the combination of compound of Formula I with antidiabetic agent where the two components are delivered in a simultaneous manner, where the compound of Formula I is administered first, followed by the antidiabetic agent, as well as wherein the antidiabetic agent is delivered first followed by the compound of Formula I.

The invention relates to oral hypoglycemic peptide as well as a fatty acid derivative and application thereof. The sequence of the polypeptide is shown in SEQ ID NO.1. The polypeptide or the fatty acid derivative can be used for preparing a drug or a drug composition for preventing or treating diabetes or preparing a hypoglycemic drug or drug composition. Compared with the prior art, the polypeptide can well prevent enzymolysis ineffectiveness in gastrointestinal tracts for enzymolysis resistance of protease and is more suitable to be used as an oral hypoglycemic drug.

Oral hypoglycemic polypeptide is an Exendin-4 analogue and is obtained by replacing twelfth, twentieth and twenty-seventh amino acids in an amino acid sequence of the Exendin-4 with non basic amino acids. Compared with an Exendin-4 archetype, the enzymatic hydrolysis resistance of the oral hypoglycemic polypeptide is remarkably improved, and the hypoglycemic polypeptide can be orally taken and has a good application prospect in treatment of type II diabetes mellitus.

The invention relates to an oral suspension of a liposome-encapsulated insulin lyophilized preparation, named as O-SCULI. The O-SCULI contains lecithin, cholesterol, polyglycol aliphatic acid ester, vitamin E, insulin, water, sodium chloride and phosphate buffer. The invention also provides a two-step process of the O-SCULI, comprising (1) a dewatering / moistening control process: preparing a liposome-encapsulated insulin lyophilized preparation and SCLI so that the encapsulation rate of the insulin is increased to 80 percent by liposome amalgamation; and (2) a respective constant volume / stepped liquefaction process: preparing the SCLI into an O-SCULI oral suspension, preventing the SCLI liposome from leaking and keeping the constant encapsulation rate of the insulin. After a patient acutely takes the O-SCULI, the liposome insulin effectively enters the intestine-hepatic portal vein, the liver and the blood circulation to reduce blood sugar, blood fatty acids and blood ketone with high utilization degree. After a patient continuously orallly takes the oral suspension, the saccharification of hematoglobin, triglyceride and, aminotransferase and the oxidative stress are reduced, the structural damage of liver cells is recovered, and the comprehensive curative effects of diabetes treatment by using various liver functions are improved. The invention also opens up a new path for non-injection administration of active polypeptide protein, such as cytochrome C, albumin, interferon, and the like.

The present invention relates to a pharmaceutical composition containing a G protein coupled receptor 119 (GPR119) ligand as an active ingredient for preventing or treating non-alcoholic fatty liver disease. More particularly, it was confirmed that the GPR119 ligand, which has been developed as only an anti-diabetic drug, exhibits superior effects on the treatment of non-alcoholic fatty liver and the signal pathways in hepatocytes therefor differ from the signal pathways in the small intestine and the pancreas exhibiting anti-diabetic effects, whereby the GPR119 ligand can be useful to treat non-alcoholic fatty liver.

The present invention relates to a method for suppressing the fasting plasma insulin level and / or postabsorptive insulin level in a mammal in need thereof, said method comprising administering to said mammal a pharmaceutically effective amount of a combination of a potassium channel activator and an anti-diabetic drug. The present invention also relates to a method for treating or preventing obesity, obesity related disorders and conditions and other disorders and conditions related to weight gain in a mammal in need thereof, said method comprising administering to said mammal a pharmaceutically effective amount of a combination of a potassium channel activator and an anti-diabetic drug.

The invention provides methods for treating a patient having type 2 diabetes who has failed on previous regimens of one or more oral and / or injectable anti-diabetic agents, which include the step of administering a therapeutically effective amount of an SGLT2 inhibitor alone or in combination with another anti-diabetic agent and / or other therapeutic agent to such patient. A pharmaceutical composition containing dapagliflozin or dapagliflozin-S-propylene glycol solvate and one or more diabetic agents and / or other therapeutic agents for use in the methods of the invention is also provided.

The invention relates to a use of a szechuan melandium root pentacyclic triterpenoid saponin compound in preparation of a drug for reducing blood sugar. Through massive screening and research, the inventor first finds the szechuan melandium root pentacyclic triterpenoid saponin compound extracted from a caryophyllaceae plant szechuan melandium root, purifies it and especially finds that a composition of a compound with sinocrassuloside as a mother nucleus and the szechuan melandium root pentacyclic triterpenoid saponin compound has strong blood sugar-reduction effects and can be used for preparation of anti-diabetic drugs.

The present invention relates to orally administered pharmaceutical compositions that include a combination of antidiabetic agents wherein one agent is present in an extended release form and the other agent is present in an immediate release form. For example, in one embodiment the dosage form includes an extended release layer that includes a biguanide; and an immediate release layer that includes a sulfonylurea.

The present invention relates to pharmaceutical compositions comprising {2-[3-cyclohexyl-3-(trans-4-propoxy-cyclohexyl)-ureido]-thiazol-5-ylsulfanyl}-acetic acid (FRI-1) in combination with an anti-diabetic drug selected from the group consisting of metformin, sitagliptin or exenatide. The present invention also relates to the use of the pharmaceutical compositions in restoring insulin sensitivity and treating type II diabetes, including reducing body weight in subjects undergoing type II diabetes treatment.

The invention belongs to the field of medicine, and relates to a pharmaceutical application of an oral hypoglycemic drug metformin, and especially relates to an application of metformin on preparation drugs for reducing surface antigen level of hepatitis B virus. The results of in-vitro cell culture tests and drug intervention tests show that metformin can prominently reduce HBsAg titer of stable cell line HepG 2.2.15 and HBeAg titer of cell culture supernatant, and has an inhibition tendency on HBV-DNA of HepG 2.2.15 cell culture supernatant and HBV replication intermediates in cells. The metformin can be used to prepare drugs for inhibiting HBsAg, and furthermore, can be used to prepare drugs for reducing or eliminating serum surface antigen of hepatitis B virus chronic infection patients, drugs for reducing or inhibiting core antigen of hepatitis B virus, and drugs for inhibiting DNA and virus replication intermediates of hepatitis B virus.

Provided are an oral hypoglycemic peptide, and a fatty acid derivative and use thereof. The sequence of the polypeptide is as shown in SEQ ID NO.1. The polypeptide or fatty acid derivative thereof may be used to prepare drugs or pharmaceutical compositions for preventing or treating diabetes, or may be used to prepare drugs or pharmaceutical compositions for lowering blood sugar. The polypeptide possesses enzymolysis resistance against a variety of proteases, may prevent failures caused by enzymolysis in the gastrointestinal tract, and is suitable as an oral hypoglycemic drug.

The present invention relates to a cell model for sieving diabetes resistant medicine and a preparation method thereof. A technical problem for solving is to provide a medicine sieving cell model which is provided with definite medicine effect mechanism and direct, prompt, simple and convenient medicine filtration and is fit for high-throughput medicine sieving and a corresponding sieving method. The cell model of the present invention is mammalian cell which clones the coding sequence of IR gene, the coding sequence of STAT5B gene and the coding sequence of reporter gene which is regulated by STAT5B responsive element. The present invention can indirectly monitor IRTK activity by inspecting reporter gene expression level in the cell model to exactly sieve the diabetes resistant medicine with the high-throughput of the cell level.

The invention provides a composition of anti-diabetic drugs. The composition comprises alogliptin coated pellets, pioglitazone coated pellets and a gelatin capsule shell and is used for treating type II diabetes, wherein blank pellets comprise main drugs, filling agents and adhesives; in the total blank pellets, the main drugs account for 3-12wt%, the filling agents account for 20-60wt%, blank pellet cores account for 40-80wt% and the adhesives account for 1-10wt%; the weights gained by coating layers are about 2-10% of the weights of the drug-loaded blank pellets. Alogliptin and pioglitazone pellets with different coating colors are preferentially prepared. The composition has the advantages of simple and reliable production process, low loss, good product stability and few by-products, so that the composition is beneficial to large-scale industrial production.